SciELO - Scientific Electronic Library Online

 
vol.37 issue2Study on the usage, effectiveness, and toxicity associated to treatment with sorafenibInfluence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343

Abstract

BUONTEMPO, F.; MORETTON, M. A.; QUIROGA, E.  and  CHIAPPETTA, D. A.. Extemporaneous clobazam suspensions for paediatric use prepared from commercially available tablets and pure drug. Farm Hosp. [online]. 2013, vol.37, n.2, pp.103-110. ISSN 2171-8695.  https://dx.doi.org/10.7399/FH.2013.37.2.117.

Objective: Two clobazam aqueous suspensions for paediatric oral usage (5 mg/ml) were investigated to determinate its physicochemical stability under different storage conditions. Method: Formulations were stored at 4 and 25 oC and the clobazam content was determined by High Performance Liquid Chromatography. Each sample was analyzed by triplicate at different time points (0, 7, 14, 28 and 56 days). Results: Liquid suspensions were successfully formulated from pure drug and commercially available tablets. In both cases, samples showed suitable physical stability. Clobazam was chemically stable in aqueous suspension during the 56 days of the study at the two storage temperatures. Conclusions: All the tried oral liquid formulations can be conserved at 4 and 25 oC at least 56-day period.

Keywords : Antiepileptic drugs; Clobazam; Epilepsy; Paediatric oral suspension; Stability.

        · abstract in Spanish     · text in English     · English ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License